A view on drug resistance in cancer
The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist
approach to define and separate the key determinants of drug resistance, which include …
approach to define and separate the key determinants of drug resistance, which include …
Liquid biopsy and minimal residual disease—latest advances and implications for cure
Liquid biopsy has been introduced as a new diagnostic concept predicated on the analysis
of circulating tumour cells (CTCs) or circulating tumour-derived factors, in particular, cell-free …
of circulating tumour cells (CTCs) or circulating tumour-derived factors, in particular, cell-free …
Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2 …
FC Bidard, VG Kaklamani, P Neven… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Patients with pretreated estrogen receptor (ER)–positive/human epidermal
growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis …
growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis …
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Tumor molecular profiling is a fundamental component of precision oncology, enabling the
identification of genomic alterations in genes and pathways that can be targeted …
identification of genomic alterations in genes and pathways that can be targeted …
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on …
Background In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor
palbociclib and fulvestrant was associated with significant improvements in progression-free …
palbociclib and fulvestrant was associated with significant improvements in progression-free …
Overcoming endocrine resistance in breast cancer
Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …
Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
The genomic landscape of endocrine-resistant advanced breast cancers
We integrated the genomic sequencing of 1,918 breast cancers, including 1,501 hormone
receptor-positive tumors, with detailed clinical information and treatment outcomes. In 692 …
receptor-positive tumors, with detailed clinical information and treatment outcomes. In 692 …
Palbociclib in hormone-receptor–positive advanced breast cancer
Background Growth of hormone-receptor–positive breast cancer is dependent on cyclin-
dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 …
dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 …
Breast cancer treatments: updates and new challenges
A Burguin, C Diorio, F Durocher - Journal of personalized medicine, 2021 - mdpi.com
Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …